Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Part of paid clinical trials in San Diego, California.

Sponsor
Peter Zage
Study ID
NCT03611595
Phase
PHASE1
Status
Completed

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
2 Years - 26 Years
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles
  • 13-cis-retinoic acid — DRUG
    13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).

Study Details

This study is being conducted in order to determine the safety, dose-limiting toxicities, and maximum tolerated dose of cabozantinib in combination with 13-cis-retinoic acid in patients with relapsed or refractory solid tumors including tumors of the central nervous system (CNS)

Key Dates

Start date
Aug 28, 2018
Status verified
Apr 2026
Primary completion
Feb 24, 2026
Completion
Mar 23, 2026

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cabozantinib and 13-cis-retinoic acid
    Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles, combined with 13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).

Primary Outcome Measure

maximum tolerated dose of cabozantinib plus 13-cis-retinoic acid [ Time Frame: 12 months ]

Locations (2)

FacilityCityStateZIPSite coordinators
Rady Children's Hospital - San DiegoSan DiegoCalifornia92123-
Children's Healthcare of AtlantaAtlantaGeorgia30322-

Find similar trials in San Diego, CA

By research site
Rady Children's Hospital - San Diego· San Diego, CAChildren's Healthcare of Atlanta· Atlanta, GA

Related Studies